AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01392313 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Carnitine placebo
Study NCT01449682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ozurdex
Description: 0.7 mg intravitreal DEX implant on first visit, then PRN if evidence of macular edema on OCT studies
Study NCT01449682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ozurdex
Description: 0.7 mg intravitreal DEX implant on first visit then every 16 weeks
Study NCT03703830 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerebellar transcranial direct current stimulation
Description: Cerebellar transcranial direct current stimulation (ctDCS) will be applied during 25 minutes at 2 mA of intensity. Anodal electrode will be positioned 1 cm below inion and cathodal electrode at right deltoid muscle.
Study NCT03703830 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill locomotor training
Description: The Treadmill Locomotor Training (TLT) will be performed through speed and step length progression protocol for 25 minutes and combined to ctDCS
Study NCT03703830 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Treadmill locomotor training
Description: The Treadmill Locomotor Training (TLT) will be performed through speed and step length progression protocol for 25 minutes and combined to ctDCS
Study NCT03703830 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Cerebellar transcranial direct current stimulation
Description: Sham Cerebellar transcranial direct current stimulation (ctDCS sham) will be applied during 30 seconds at 2 mA of intensity. Anodal electrode will be positioned 1 cm below inion and cathodal electrode at right deltoid muscle. However, subjects will keep the placement of electrodes for 25 minutes to ensure stimulation's masking.
Study NCT03703830 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerebello-spinal direct current stimulation
Description: Cerebello-spinal transcranial direct current stimulation (csDCS) will be applied during 25 minutes at 2 mA of intensity. The anode was placed on the scalp over the cerebellum area (1 cm below the inion) and the cathode over the spinal lumbar enlargement (2 cm under T11)
Study NCT03703830 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham cerebello-spinal direct current stimulation
Description: Sham cerebello-spinal direct current stimulation (csDCS sham) will be applied during 30 seconds at 2 mA of intensity. The anode was placed on the scalp over the cerebellum area (1 cm below the inion) and the cathode over the spinal lumbar enlargement (2 cm under T11). However, subjects will keep the placement of electrodes for 25 minutes to ensure stimulation's masking.
Study NCT03700008 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Speech analysis tool
Description: Using the speech analysis tool with recording 120 seconds of free speech and analysis of 200 content-free parameters of the speech including factor analytic process to compress the data to 5-10 core parameters.
Study NCT03700008 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Conventional psychological measurements
Description: Using well known and validated psychological measurements to identify the mental state of the participants.
Study NCT04224896 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: UPPER ENDOSCOPY
Description: UPPER ENDOSCOPY
Study NCT02370498 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 200 mg administered as IV infusion on Day 1 of each 21-day cycle.
Study NCT02370498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: 80 mg/m\^2 administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle.
Study NCT03772938 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Stem/progenitor cells transplantation
Description: Human autologous bone marrow-derived stem/progenitor cell transplantation administered as an intravitreal injection in patients with degenerative disease of retina.
Study NCT03772938 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Stem/progenitor cells transplantation
Description: Human autologous bone marrow-derived stem/progenitor cell transplantation administered as an intravitreal injection in patients with degenerative disease of retina.
Study NCT03838770 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: Active target 2.0mA tDCS (n=60)
Study NCT03838770 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham tDCS
Description: sham left-anodal dorsolateral prefrontal cortex (DLFPC) montage
Study NCT01869062 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SonR CRT Optimization 'On'
Description: Intervention: Implanted CRT-D device with the SonR optimization algorithm programmed being 'on'.
Study NCT01869062 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SonR CRT Optimization 'Off'
Description: Intervention: Implanted CRT-D device with the SonR optimization algorithm programmed being 'off' (Standard of Care).
Study NCT04204655 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: BIA
Description: Bioelectrical Impedance Analysis
Study NCT00354263 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMP321
Description: This study is a single centre, single blind, placebo (step 1) or reference (step 2) randomised study. Healthy young male volunteers will receive single ascending dose of IMP321 in each step (4 doses tested: 3, 10, 30 and 100 µg). In step 1, IMP321 will be given alone and tested versus placebo (physiological saline). In step 2, the association IMP321 + Agrippal (commercially available flu vaccine) will be tested versus Agrippal alone.
Study NCT00354263 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: saline injected alone in step 1 or mixed with Aggripal in step 2
Study NCT02291471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T0001，75mg
Study NCT04537871 — intervention group
Intervention type: PROCEDURE
Intervention: Bioelectric Impedance Analysis
Description: Undergo bioelectric impedance analysis
Study NCT04537871 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT04537871 — intervention group
Intervention type: PROCEDURE
Intervention: Cardiopulmonary Exercise Testing
Description: Undergo cardiopulmonary exercise test
Study NCT04537871 — intervention group
Intervention type: PROCEDURE
Intervention: Echocardiography
Description: Undergo echocardiogram
Study NCT04537871 — intervention group
Intervention type: PROCEDURE
Intervention: Physical Performance Testing
Description: Undergo physical function tests
Study NCT04537871 — intervention group
Intervention type: PROCEDURE
Intervention: Pulmonary Function Test
Description: Undergo pulmonary function test
Study NCT04537871 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04537871 — intervention group
Intervention type: PROCEDURE
Intervention: Ultrasound
Description: Undergo musculoskeletal ultrasound
Study NCT01652729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide once weekly suspension
Study NCT01652729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Study NCT01652729 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsule once daily
Study NCT03803033 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical pharmacy-based home medication management review service
Description: A baseline interview by the clinical pharmacist was conducted with patients at their homes to assess their use of treatment and to collect all relevant information needed to identify TRPs. Upon TRP identification at baseline, the clinical pharmacist generated a written report of findings and recommendations, which was delivered directly to the patient's physician in a sealed envelope. Patients were asked to refer back to their physicians if they required confirmation of any changes in treatment. Physicians maintained the blinding of patients with regard to whether changes were based on recommendations by the pharmacist. In both the intervention and the control groups, the clinical pharmacist performed a follow-up interview with patients 3 months after the initial interview, during a regular follow-up visit to their physician at the hospital. Assessments in the follow-up interview, regardless of the study group, involved changes in treatment and number of TRPs.
Study NCT04470531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral co-trimoxazole
Description: oral co-trimoxazole + standard therapy
Study NCT01269450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: micronized progesterone 200 mg (Utrogestan)
Description: micronized progesterone 200 mg (Utrogestan, company) as an intra-vaginal tablet once daily
Study NCT01269450 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 200mg vaginal tablets
Study NCT03777904 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum Ferritin level
Description: Serum ferritin level will be collected with other clinical labs and measured in the research lab
Study NCT03777904 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum Ferritin iron content
Description: Blood will be collected with other clinical labs and the iron content in the ferritin will be measured in the research lab
Study NCT03777904 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urine Ferritin level
Description: Urine will be collected non-invasively and analyzed for ferritin level
Study NCT03777904 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urine ferritin iron content
Description: Urine will be collected non-invasively and analyzed for iron content within the ferritin
Study NCT03220126 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3074828
Description: Administered IV
Study NCT03220126 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY900021
Description: Administered SC
Study NCT03812991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miacalcin Calcitonin Salmon Nasal Spray
Description: Miacalcin nasal spray is 1 spray (200 International Units) per day administered intranasally, alternating nostrils daily
Study NCT01837433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 1 week
Description: Prednisone 1 week 30mg/day and Celecoxib 400mg in first day, and then 200mg bid in the remaining next week, total 2 weeks.
Study NCT01837433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone 6 weeks
Description: Guidelines recommend
Study NCT03158025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem tablets
Description: Zolpidem 3 x 10 mg tablets will be administered orally.
Study NCT01471613 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet, orally administration of placebo for 6 weeks
Study NCT02622269 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient-regulated compression device
Description: Compression of the abdomen with a patient-regulated compression device
Study NCT02622269 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard compression device
Description: Compression of the abdomen with the standard compression device
Study NCT02507245 — intervention group
Intervention type: DRUG
Intervention: Growth Hormone-Releasing Hormone
Description: From Baseline Visit (T0) to 6th Month Visit 0,025 mg/kg Growth Hormone/die. From 6th Month Visit to 12th Month Visit 0,030 mg/Kg Growth Hormone/die.
Study NCT03922412 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PLANTAR BLOCK
Description: 1. Sciatic popliteal block : patient in lateral position, injection of 20 ml of the mixture labelled  BLOC POPLITE  containing 20 ml of mepivacain 1% (200mg)~2. Plantar block 10 minutes later : patient in supine position. Medial midfoot injection of 5 ml of the mixture labelled  BLOC PLANTAIRE  containing 5 ml of Ropivacaine 0,5% (25mg) with 0,5 ml dexaméthasone (2mg)~3. Distal deep fibular block : patient in supine position, injection around the dorsal foot artery of 2 ml of the mixture labelled  BLOC FIBULAIRE  containing 2 ml of Ropivacaine 0,5% (10mg).
Study NCT03922412 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sciatic popliteal block
Description: 1-Sciatic popliteal block : patient in lateral position, injection of 20 ml of the mixture labelled  BLOC POPLITE  containing 20 ml of ropivacaine 0,5% (100mg) with 2mg (0,5 ml) of dexamethasone
Study NCT01356758 — intervention group
Intervention type: DRUG
Intervention: biological treatment
Description: patients treated with anti-psoriatic biological agents
Study NCT01764815 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: directSTN Acute lead connected to external neurostimulator
Description: Test phase will be performed intra-operatively, prior to chronic lead implant
Study NCT03141333 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teleintervention
Description: Participants of this group will have access to the following sections in the web plate-form: information, forum, chat and live online consultation. The teleintervention consists of having access to the forum, chat and live online consultation sections of the web plate-form.
Study NCT05211011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin
Description: Infectofos 5 g
Study NCT02213302 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo administration
Study NCT04382365 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sleep Health Using the Internet for Older Adult Sufferers of Insomnia and Sleeplessness
Description: Cognitive-Behavioral Treatment for insomnia (CBT-I) is a non-pharmacological intervention that is effective in treating insomnia in older adults, even when present with comorbid medical and psychological conditions.25 CBT-I focuses on the maladaptive behaviors and dysfunctional thoughts that perpetuate sleep problems, and typically consists of five primary treatment components: sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention.
Study NCT00889499 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tropisetron 2 mg
Description: Antagonist of the 5HT3 receptor.
Study NCT00889499 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tropisetron 5mg
Description: Antagonist of the 5HT3 receptor.
Study NCT00889499 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NHCL 0,9%
Study NCT02213302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo administration
Study NCT02213302 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: midazolam intravenous administration
Study NCT02213302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam intravenous administration
Study NCT00617409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: All groups wil receive paclitaxel as second line chemotherapy if their cancer spreads. At any point when a patient develops evidence of progressive disease, the patient will be treated with second-line chemotherapy. Paclitaxel will be given at a dose of 200 mg/m² on day 1 of 21 day cycles.
Study NCT00617409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: All groups wil receive paclitaxel as second line chemotherapy if their cancer spreads. At any point when a patient develops evidence of progressive disease, the patient will be treated with second-line chemotherapy. Paclitaxel will be given at a dose of 200 mg/m² on day 1 of 21 day cycles.
Study NCT00617409 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Drug: Ad.p53-DC vaccines
Description: Patients randomized to Arm B will receive vaccinations on 3 occasions, at 2 week intervals. 1-5x106 p53 positive DCs in 1 ml will be injected intradermally into 4 separate sites (0.25 ml injected at each site), in bilateral proximal upper and lower extremities (in the regions of the axillary and inguinal nodal basins). Patients will be restaged approximately 2-3 weeks after vaccine # 3 (first vaccine course). If patients show no sign of disease progression at restaging, then a second leukopheresis will be performed. Patients will then be vaccinated 3 more times (second vaccine course) at 4-week intervals, for a total of 6 possible vaccines. Restaging will occur 2-4 weeks after completing the second vaccine course. Patients in Arm C will receive vaccines at the same dose and schedule as described for patients in Arm B. In addition, they will receive 150 mg/m² of ATRA for 3 days prior to each vaccine administration (followed by vaccine administration on the fourth day).
Study NCT00617409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All -trans Retinoic Acid (ATRA)
Description: The patients in Arm C will receive vaccines at the same dose and schedule as described for patients in Arm B. In addition, they will receive 150 mg/m² of ATRA for 3 days prior to each vaccine administration (followed by vaccine administration on the fourth day).
Study NCT02399865 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Youth Social Behaviour and Network Therapy
Description: The Y-SBNT will be delivered according to the developed purpose-designed therapy manual. Participants randomised to Y-SBNT will be offered six, 50 minute SBNT sessions for over a maximum period of 12 weeks. Where consent is obtained, sessions will audio-recorded and reviewed by the research team to ensure fidelity with the YSBNT manual and principles of practice.~Using the identification of the social network of the young person conducted in the first session as a platform, subsequent core strategies of the adapted YSBNT approach include motivational techniques, improving communication and coping mechanisms, and crucially given the nature of substance misuse, developing a network-based relapse management plan. Participants will be given the opportunity to invite members of their network to the treatment sessions. The therapeutic approach also has scope to address client-focussed elective areas, for example, educational requirements.
Study NCT00969371 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: posterior chamber IOL implantation
Study NCT00969371 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental TetraFlex Study IOL
Description: TetraFlex IOL implanted
Study NCT01962844 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coconut Oil
Description: Patients were followed for 6 months with dietary treatment. Beginning supplementation with coconut oil extra virgin from the third month of intervention nutrition. Coconut oil was consumed neat or added to fruit.
Study NCT01962844 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Diet
Description: Patients were instructed to follow the dietary treatment for 6 months
Study NCT02512965 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 20 Gy in 5 fractions
Study NCT02512965 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Conventional SBRT: 24 Gy in 2 fractions
Study NCT03573284 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: fractional exhaled nitric oxide(FeNO)
Description: FeNO level was evaluated according to the American Thoracic Society (ATS)/ERS recommendations using a NIOX MINO analyzer (Aerocrine, Solna, Sweden) .Subjects were informed to deeply inhale NO-free air and immediately exhale in full via a mouthpiece at a constant flow rate (50 ml/s) for 10s.
Study NCT03573284 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: impulse oscillometry(IOS)
Description: The patient take seats, body relax, make sure the mouthpiece is fully covered by mouth, then clip nose with both hands to cover both sides of the cheek, and then calm breathing 1 minutes, the computer is automatically collected data calculation and print out the measurement results.
Study NCT00835770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate
Description: BG00012 capsules
Study NCT00835770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules taken to maintain the blind in the 240 mg BID treatment group.
Study NCT03443453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIV-711
Description: MIV-711 administered as tablets and capsules at four occasions
Study NCT02434107 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Completion Lymphadenectomy
Study NCT01579760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept every 2 months
Description: 2.0 mg aflibercept intravitreal injections once per month for the first 3 months (M0, M1, M2), then every 2 months (M4, M6, M8, M10)
Study NCT01579760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept monthly
Description: 2.0mg aflibercept intravitreal injections every month (M0-11)
Study NCT04661826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oncofid-P-B
Description: Paclitaxel - Hyaluronic Acid 600 mg - Solution for intravesical administration.
Study NCT03171441 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: nailfold videocapillaroscopy
Description: non-invasive nailfold videocapillaroscopy
Study NCT03171441 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: inflammatory biomarkers
Description: blood sample collection to asses leptin and C-reactive protein
Study NCT03389256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib mesylate tablets 250 mg qd po, if the patient can tolerate the toxic side effects, adjust the dose to 500mg qd po after 1 week.
Study NCT03389256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EGFR-TKI
Description: Imatinib tablets, 125 mg tid po; gefitinib tablets, 250 mg qd po; erlotinib tablets, 150 mg qd po